Norris Medicines Ltd (NORRIS) is currently trading at 16.77 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Norris Medicines Limited is a key player in the healthcare industry, primarily focusing on the manufacturing of injections and medicinal formulations. The company operates two WHO GMP-approved plants in Ankleshwar, Gujarat. Significant milestones in its portfolio include the introduction of diabetic and cardiac products in 2006, a dental range in 2007, and an enhanced anti-malarial range by 2013. This highlights its expanding and diverse product line over the years. The company made strategic expansions early on by manufacturing sterile dosage forms like ampoules and vials, significantly upgrading its sterile injectable plant to meet international standards. Norris Medicines' trajectory since its establishment in 1990 shows a clear pattern of growth and diversification, buttressed by initial public financing and subsequent capacity augmentations. Its emphasis on maintaining high compliance standards with WHO GMP certifications underscores its commitment to quality and global competitiveness in pharmaceutical manufacturing.

Over the past 52 weeks, Norris Medicines Ltd has traded between a low of ₹12.00 and a high of ₹19.63. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Norris Medicines Ltd has a market capitalization of approximately 15.98. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Norris Medicines Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -43.19 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 15.98 Cr, Norris Medicines Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Norris Medicines Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Norris Medicines Ltd is -43.19. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.